Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

The First Trust NYSE Arca Biotechnology ETF (FBT), a smart beta fund managing over $1.04 billion, provides concentrated exposure to the biotechnology sector via an equal-dollar weighted index. Despite a 0.54% expense ratio and a 3.43% year-to-date return, FBT is identified as a high-risk option due to its 20.17% trailing three-year standard deviation and a relatively concentrated portfolio of 31 holdings. This positions FBT as a more volatile alternative compared to larger, lower-cost peer funds like XBI and IBB for investors targeting outperformance in the healthcare segment.

Analysis

The First Trust NYSE Arca Biotechnology ETF (FBT) is a smart beta fund with over $1.04 billion in assets, offering specialized exposure to the biotechnology sector through an equal-dollar weighted index. This strategy deviates from traditional market-cap-weighted funds by providing balanced exposure across its approximately 31 holdings, with its top 10 positions comprising 38.35% of total assets. Despite its focused approach, the fund's performance has been modest, with a year-to-date return of 3.43% and a one-year return of 1.68%. The fund's risk profile is notably high, characterized by a trailing three-year standard deviation of 20.17%, leading the article to classify it as a high-risk choice with concentrated exposure. Its 0.54% expense ratio is higher than larger, more liquid competitors like the SPDR S&P Biotech ETF (XBI) at 0.35% and the iShares Biotechnology ETF (IBB) at 0.45%, positioning FBT as a niche, higher-cost option for investors specifically seeking an equal-weighted methodology.

Key Decisions for Investors

• Investors seeking an equal-weighted, non-market-cap-driven exposure to the biotechnology sector could consider FBT, but must be prepared to accept higher volatility and concentration risk compared to broader market-cap ETFs.
• The fund's 0.54% expense ratio and 20.17% standard deviation warrant careful consideration, and investors should weigh whether the potential benefits of its smart beta strategy justify these higher costs and risks.
• It is prudent to compare FBT's performance, cost, and risk profile directly against larger, lower-cost alternatives mentioned, such as XBI and IBB, to determine the most suitable vehicle for healthcare sector allocation.
• Given its modest recent returns, investors should monitor the fund for evidence that its equal-weighting methodology can generate alpha sufficient to compensate for its relatively high risk and fees over a full market cycle.